HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fournier's European Strategy

Executive Summary

To reduce its dependence on a stagnant and price sensitive French market, Fournier has created a low-risk R&D program coupled with an aggressive international acquisition program. The program attempts to take advantage of small-market research opportunities as well as acquisition targets overlooked by large companies or which fall out of mega-mergers. Is this gamble enough to ensure independence for a mid-sized player?

You may also be interested in...



Nous Voici! Sanofi's Leap to the World Stage

Still as French as they come, Sanofi's extraordinary international success--its P/E and growth rate are among the industry's highest--has been due to two factors. The first is its productive research group, which has eschewed most biotech fashions in favor of a conservative, small-molecule, therapeutically focused R&D program. The second has been its joint venture with Bristol-Myers on two of its most important products, a joint venture which allowed Sanofi, in a protected fashion, to learn to compete internationally against the most powerful pharmaceutical marketers in the world. If the company has an Achilles' heel, it is the francocentrism of its marketing and development, and perhaps research as well.

US FDA Not Changing Assessment Goals Because of Coronavirus-Mandated Telework

Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.

Topics

Related Companies

UsernamePublicRestriction

Register

IV000470

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel